ForPatients
by Roche

NeoplasiasCâncer

Estudo de extensão multicêntrico, de braço único, aberto, de bevacizumabe em pacientes com tumores sólidos recebendo o tratamento do estudo com bevacizumabe no final de um estudo patrocinado pela F. Hoffmann-La Roche e/ou Genentech.

Trial Status	Trial Runs In	Trial Identifier
Concluído	21 Countries	NCT01588184 2011-002009-31 MO25757

As informações abaixo foram obtidas diretamente de sites de registro público, como ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com etc., e não foram editadas.

Official Title:

A Single Arm, Open Label Multicentre Extension Study of Bevacizumab in Patients With Solid Tumours on Study Treatment With Bevacizumab, at the End of A F. Hoffmann-La Roche and/or Genentech Sponsored Study

Trial Summary:

Estudo de fase IIIb/IV, multicêntrico, aberto, de braço único. Pacientes recebendo bevacizumabe no final do P-estudo devem ser incluídos imediatamente a partir daí. Os pacientes receberão tratamento com bevacizumabe como durante seu P-estudo até a progressão da doença, toxicidade inaceitável, retirada do consentimento ou morte (o que ocorrer primeiro).

Hoffmann-La Roche	Phase 4
Sponsor	Phase

NCT01588184 2011-002009-31 MO25757
Trial Identifiers

Eligibility Criteria:

Gender	Age	Healthy Volunteers
All	#18 Years	No

Inclusion Criteria:

- Participant is treated with bevacizumab at the end of the Roche/Genentech sponsored parent trial and continues to have benefit as judged by the investigator
- Eligible for continuation of bevacizumab treatment at the end of a parent trial, according to parent trial protocol
- Able to comply with this extension study protocol (MO25757)

Exclusion Criteria:

- Evidence of disease progression assessed according to parent trial protocol during the screening phase for this extension study
- Evidence of any adverse event potentially attributable to bevacizumab, for which the local label recommends permanent discontinuation
- A treatment interruption with bevacizumab of more than 42 days since the last administration of bevacizumab in the parent trial
- Evidence of any other disease that would put the participant at high risk for treatment-related complications